Everolimus to prevent transplant rejection
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000243
English, French
Authors' objectives:
To summarize the available information on the use of everolimus (Trade Name: Certican; manufactured by Novartis Pharmaceuticals) with cyclosporine for the prevention of rejection episodes after heart or kidney transplantation.
Authors' recommendations:
Immunosuppression is a delicate balancing act: there are consequences from both under-immunosuppression and over-immunosuppression after transplantation. The ideal agent or combination of agents has not yet been found. The immunosuppressant examined here, everolimus, may help to prevent graft rejection in some patients. Efficacy has been shown in heart and kidney transplant procedures. Its use in other types of transplantation is being explored.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Heart Transplantation
- Immunosuppression Therapy
- Kidney Transplantation
- Graft Rejection
- Transplants
- Everolimus
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment(CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.